Mark Petrie is Professor of Cardiology at the University of Glasgow. He worked as a clinician with a sub-speciality interest in heart failure, advanced heart failure and interventional cardiology before accepting a formal academic role 2 years ago. He is also on the steering and executive committees of many trials (including intravenous iron, various interventional heart failure therapies, trials of coronary artery disease and HF (STICH and REVIVED) and others). He was an author of the ESC NSTEMI guidelines and a senior author of the ESC Position Statement on Diabetes and Heart Failure. He is involved in ongoing trials of diabetes therapies in cardiovascular disease and heart failure. One of his major interests is peripartum cardiomyopathy (member of the Executive Committee and Steering Group of the ESC Peripartum Cardiomyopathy Registry). Mark is the UK Lead for PARADISE-MI and Dapa-HF and has also served on the Clinical Events Committee of over 30 trials including EMPA-REG OUTCOME, TRUE-HF, ASCEND, the original HARMONY programme, CARMELINA and CAROLINA amongst many others.